Literature DB >> 29644743

Letter: infliximab concentrations during induction therapy-one size does not fit all.

K Papamichael1, A S Cheifetz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29644743      PMCID： PMC6375710          DOI： 10.1111/apt.14616

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  9 in total

1.  Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.

Authors:  H Bar-Yoseph; N Levhar; L Selinger; U Manor; M Yavzori; O Picard; E Fudim; U Kopylov; R Eliakim; S Ben-Horin; Y Chowers; B Ungar
Journal:  Aliment Pharmacol Ther       Date:  2017-11-09       Impact factor: 8.171

Review 2.  Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.

Authors:  Konstantinos Papamichael; Niels Vande Casteele; Marc Ferrante; Ann Gils; Adam S Cheifetz
Journal:  Inflamm Bowel Dis       Date:  2017-09       Impact factor: 5.325

3.  Antibody response to infliximab and its impact on pharmacokinetics can be transient.

Authors:  Niels Vande Casteele; Ann Gils; Sharat Singh; Linda Ohrmund; Scott Hauenstein; Paul Rutgeerts; Séverine Vermeire
Journal:  Am J Gastroenterol       Date:  2013-02-19       Impact factor: 10.864

4.  Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.

Authors:  Konstantinos Papamichael; Thomas Van Stappen; Niels Vande Casteele; Ann Gils; Thomas Billiet; Sophie Tops; Karolien Claes; Gert Van Assche; Paul Rutgeerts; Severine Vermeire; Marc Ferrante
Journal:  Clin Gastroenterol Hepatol       Date:  2015-12-08       Impact factor: 11.382

5.  Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.

Authors:  Omoniyi J Adedokun; William J Sandborn; Brian G Feagan; Paul Rutgeerts; Zhenhua Xu; Colleen W Marano; Jewel Johanns; Honghui Zhou; Hugh M Davis; Freddy Cornillie; Walter Reinisch
Journal:  Gastroenterology       Date:  2014-08-28       Impact factor: 22.682

6.  Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis.

Authors:  Johannan F Brandse; Ron A Mathôt; Desiree van der Kleij; Theo Rispens; Yaël Ashruf; Jeroen M Jansen; Svend Rietdijk; Mark Löwenberg; Cyriel Y Ponsioen; Sharat Singh; Gijs R van den Brink; Geert R D'Haens
Journal:  Clin Gastroenterol Hepatol       Date:  2015-11-09       Impact factor: 11.382

7.  Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.

Authors:  Yana Davidov; Bella Ungar; Haggai Bar-Yoseph; Dan Carter; Ola Haj-Natour; Miri Yavzori; Yehuda Chowers; Rami Eliakim; Shomron Ben-Horin; Uri Kopylov
Journal:  J Crohns Colitis       Date:  2017-05-01       Impact factor: 9.071

8.  Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

Authors:  Lorant Gonczi; Zsuzsanna Vegh; Petra Anna Golovics; Mariann Rutka; Krisztina Barbara Gecse; Renata Bor; Klaudia Farkas; Tamás Szamosi; László Bene; Beáta Gasztonyi; Tünde Kristóf; László Lakatos; Pál Miheller; Károly Palatka; Mária Papp; Árpád Patai; Ágnes Salamon; Gábor Tamás Tóth; Áron Vincze; Edina Biro; Barbara Dorottya Lovasz; Zsuzsanna Kurti; Zoltan Szepes; Tamás Molnár; Péter L Lakatos
Journal:  J Crohns Colitis       Date:  2017-06-01       Impact factor: 9.071

9.  First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.

Authors:  Taku Kobayashi; Yasuo Suzuki; Satoshi Motoya; Fumihito Hirai; Haruhiko Ogata; Hiroaki Ito; Noriko Sato; Kunihiko Ozaki; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2015-07-11       Impact factor: 7.527
  9 in total
  1 in total

1.  Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.

Authors:  Anna Juncadella; Konstantinos Papamichael; Byron P Vaughn; Adam S Cheifetz
Journal:  Dig Dis Sci       Date:  2018-07-13       Impact factor: 3.199
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.